Galectin Therapeutics Stock Today
| GALT Stock | USD 3.03 0.22 6.77% |
Performance15 of 100
| Odds Of DistressOver 65
|
Galectin Therapeutics is selling for under 3.03 as of the 11th of May 2024; that is -6.77 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 2.92. Galectin Therapeutics has more than 65 % chance of experiencing financial distress in the next few years of operation. However, it had a very good returns during the last 90 days. Equity ratings for Galectin Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 11th of April 2024 and ending today, the 11th of May 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 9th of September 2002 | Category Healthcare | Classification Health Care |
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia. Galectin Therapeutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 61.9 M outstanding shares of which 3.12 M shares are currently shorted by private and institutional investors with about 10.22 trading days to cover. More on Galectin Therapeutics
Moving against Galectin Stock
| 0.87 | JNJ | Johnson Johnson Financial Report 18th of July 2024 | PairCorr |
| 0.87 | GLPG | Galapagos NV ADR | PairCorr |
| 0.82 | GILD | Gilead Sciences | PairCorr |
| 0.79 | EPIX | ESSA Pharma Financial Report 14th of May 2024 | PairCorr |
| 0.77 | IMTX | Immatics NV Financial Report 21st of May 2024 | PairCorr |
| 0.74 | TIL | Instil Bio | PairCorr |
| 0.71 | VRAX | Virax Biolabs Group Fiscal Year End 12th of June 2024 | PairCorr |
Galectin Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Galectin Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Galectin Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Thematic Idea | Israel Wall Street (View all Themes) | |||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Israel Wall Street, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Galectin Therapeutics report their recommendations after researching Galectin Therapeutics' financial statements, talking to executives and customers, or listening in on Galectin Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Galectin Therapeutics. The Galectin consensus assessment is calculated by taking the average forecast from all of the analysts covering Galectin Therapeutics. | ||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Galectin Therapeutics' liquidity, profitability, solvency, and operating efficiency, Galectin Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in June. Financial strength of Galectin Therapeutics is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||
Galectin Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Galectin Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Galectin Therapeutics' financial leverage. It provides some insight into what part of Galectin Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||
Galectin Therapeutics (GALT) is traded on NASDAQ Exchange in USA. It is located in 4960 Peachtree Industrial Boulevard, Norcross, GA, United States, 30071 and employs 28 people. Galectin Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 202.44 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Galectin Therapeutics's market, we take the total number of its shares issued and multiply it by Galectin Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Galectin Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 61.9 M outstanding shares of which 3.12 M shares are currently shorted by private and institutional investors with about 10.22 trading days to cover.
Galectin Therapeutics currently holds about 15.83 M in cash with (32.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.27.
Check Galectin Therapeutics Probability Of Bankruptcy
Ownership AllocationGalectin Therapeutics secures a total of 61.9 Million outstanding shares. Galectin Therapeutics secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Galectin Ownership Details
Galectin Stock Price Odds Analysis
Attributed to a normal probability distribution, the odds of Galectin Therapeutics jumping above the current price in 90 days from now is about 29.51%. The Galectin Therapeutics probability density function shows the probability of Galectin Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Galectin Therapeutics has a beta of -1.5101. This usually indicates as returns on its benchmark rise, returns on holding Galectin Therapeutics are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, Galectin Therapeutics is expected to outperform its benchmark. Moreover, galectin Therapeutics has an alpha of 1.2272, implying that it can generate a 1.23 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of Galectin Therapeutics to move above the current price in 90 days from now is about 29.51 (This Galectin Therapeutics probability density function shows the probability of Galectin Stock to fall within a particular range of prices over 90 days) .
Galectin Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Galectin Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Galectin Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Galectin Therapeutics' value.| Instituion | Recorded On | Shares | |
| 683 Capital Management Llc | 2023-12-31 | 111 K | |
| Commonwealth Equity Services Inc | 2023-12-31 | 105.4 K | |
| Northern Trust Corp | 2023-12-31 | 101 K | |
| Susquehanna International Group, Llp | 2023-12-31 | 79.1 K | |
| Qube Research & Technologies | 2023-12-31 | 75.4 K | |
| Mml Investors Services Inc | 2023-12-31 | 54.2 K | |
| Horizon Asset Management Inc/ny | 2023-12-31 | 53.7 K | |
| Lpl Financial Corp | 2023-12-31 | 51.8 K | |
| Synovus Financial Corp | 2023-12-31 | 48 K | |
| Vanguard Group Inc | 2023-12-31 | 1.9 M | |
| Advisor Group Holdings, Inc. | 2023-12-31 | 1.3 M |
Galectin Therapeutics Historical Income Statement
Galectin Therapeutics Income Statement is one of the three primary financial statements used for reporting Galectin's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Galectin Therapeutics revenue and expense. Galectin Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Galectin Therapeutics' Depreciation And Amortization is comparatively stable compared to the past year. Other Operating Expenses is likely to gain to about 40 M in 2024, despite the fact that Operating Income is likely to grow to (36.2 M). View More FundamentalsGalectin Stock Against Markets
Picking the right benchmark for Galectin Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Galectin Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Galectin Therapeutics is critical whether you are bullish or bearish towards Galectin Therapeutics at a given time. Please also check how Galectin Therapeutics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Galectin Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Volatility Now
Portfolio VolatilityCheck portfolio volatility and analyze historical return density to properly model market risk |
| All Next | Launch Module |
Galectin Therapeutics Corporate Management
Elected by the shareholders, the Galectin Therapeutics' board of directors comprises two types of representatives: Galectin Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Galectin. The board's role is to monitor Galectin Therapeutics' management team and ensure that shareholders' interests are well served. Galectin Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Galectin Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA | Treasurer CFO | Profile | |
| Jeff Katstra | Head Development | Profile | |
| Robert Tritt | General Counsel | Profile | |
| Beth Knowles | Executive Manager | Profile |
How to buy Galectin Stock?
Before investing in Galectin Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Galectin Therapeutics. To buy Galectin Therapeutics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Galectin Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Galectin Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Galectin Therapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Galectin Therapeutics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Galectin Therapeutics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Galectin Stock please use our How to Invest in Galectin Therapeutics guide.
Already Invested in Galectin Therapeutics?
The danger of trading Galectin Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Galectin Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Galectin Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Galectin Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Galectin Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Galectin Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Galectin Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Galectin Therapeutics Stock: Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galectin Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Galectin Stock please use our How to Invest in Galectin Therapeutics guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Complementary Tools for Galectin Stock analysis
When running Galectin Therapeutics' price analysis, check to measure Galectin Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galectin Therapeutics is operating at the current time. Most of Galectin Therapeutics' value examination focuses on studying past and present price action to predict the probability of Galectin Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galectin Therapeutics' price. Additionally, you may evaluate how the addition of Galectin Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |
Is Galectin Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Galectin Therapeutics. If investors know Galectin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Galectin Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.74) | Return On Assets (0.96) | Return On Equity (37.28) |
The market value of Galectin Therapeutics is measured differently than its book value, which is the value of Galectin that is recorded on the company's balance sheet. Investors also form their own opinion of Galectin Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Galectin Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Galectin Therapeutics' market value can be influenced by many factors that don't directly affect Galectin Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Galectin Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Galectin Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Galectin Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.